About QT Ultrasound® and QTbreasthealth™
QT Ultrasound® is a privately held company engaged in the research, development, and commercialization of an innovative automated breast imaging system producing high-resolution transmission ultrasound images. The company has received FDA 510(K) clearance for its QTscan, and the National Institutes of Health (NIH) awarded over $15 million in funding to continue QT Ultrasound research. The company's clinical trials have been conducted at prestigious institutions in the US and Europe and include ongoing trials at the Marin Breast Health Trial Center in Novato, California. QTscans are now available commercially through the breast imaging centers of QTbreasthealth™.


QT Ultrasound and QTbreasthealth were founded by John C. Klock, MD, who serves as Chief Executive Officer, Managing Director, and Manager. Prior to QT Ultrasound, Dr. Klock was involved in the start-up of five medical companies, including Co-Founder and President of BioMarin Pharmaceutical, which successfully commercialized five FDA approved drugs; Scientific Founder and Vice President of Research of Glycomed, now Ligand Pharmaceutical; and founding investor in Ultragenyx Pharmaceutical. He also personally brought to market a novel cancer treatment, the first rapid AIDS test, comprehensive tests for detecting metabolic diseases in children, and several drugs for treating pediatric genetic conditions. Dr. Klock has authored over 70 peer-reviewed medical and scientific publications, and eight granted patents.

The QT Ultrasound Breast Scanner has received FDA 510(k) clearance for use as an ultrasonic imaging system to provide reflection-mode and transmission-mode images of a patient's breast and is not a replacement for screening mammography.


SOURCE QTbreasthealth

Back to HCB News

Women's Health Homepage